Comparative Pharmacology
Head-to-head clinical analysis: GRISEOFULVIN ULTRAMICROSIZE versus IMPEKLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRISEOFULVIN ULTRAMICROSIZE versus IMPEKLO.
GRISEOFULVIN, ULTRAMICROSIZE vs IMPEKLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to tubulin, disrupting microtubule function and inhibiting fungal cell mitosis; deposited in keratin precursor cells, making keratin resistant to fungal invasion.
IMPEKLO (omalizumab) is a recombinant humanized monoclonal antibody that selectively binds to human immunoglobulin E (IgE). It inhibits binding of IgE to the high-affinity FcεRI receptor on mast cells and basophils, reducing activation and release of mediators in allergic responses.
250-375 mg orally once daily or 500-750 mg orally once daily for severe infections.
IMPEKLO is not a recognized pharmaceutical agent. No dosing information available.
None Documented
None Documented
9-24 hours (mean 15 hours); prolonged in liver disease.
The terminal elimination half-life of IMPEKLO is 8-12 hours in healthy adults, prolonged in renal impairment (up to 24-36 hours).
Renal (<1% unchanged); fecal (36% as metabolites); tissue deposition may persist for weeks.
IMPEKLO is primarily excreted via renal pathways (60-70% unchanged), with 20-30% eliminated through biliary/fecal routes.
Category D/X
Category C
Antifungal
Antifungal